Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies.
de Beukelaar JW, Verjans GM, van Norden Y, Milikan JC, Kraan J, Hooijkaas H, Sintnicolaas K, Gratama JW, Sillevis Smitt PA. de Beukelaar JW, et al. Among authors: van norden y. Cancer Immunol Immunother. 2007 Sep;56(9):1501-6. doi: 10.1007/s00262-007-0295-2. Epub 2007 Feb 14. Cancer Immunol Immunother. 2007. PMID: 17597332 Free PMC article.
B and T cell imbalances in CSF of patients with Hu-antibody associated PNS.
de Graaf M, de Beukelaar J, Bergsma J, Kraan J, van den Bent M, Klimek M, van Norden Y, Kusuma A, Smitt PS, Gratama JW. de Graaf M, et al. Among authors: van den bent m, van norden y. J Neuroimmunol. 2008 Mar;195(1-2):164-70. doi: 10.1016/j.jneuroim.2008.01.007. Epub 2008 Mar 20. J Neuroimmunol. 2008. PMID: 18358542
No evidence for the presence of HuD-specific T cells in the cerebrospinal fluid of patients with Hu-associated paraneoplastic neurological syndromes.
de Beukelaar JW, Milikan JC, Verjans GM, de Graaf MT, van Norden Y, Lamers CH, van den Bent MJ, Bromberg JE, Hulsenboom E, Sintnicolaas K, Gratama JW, Sillevis Smitt PA. de Beukelaar JW, et al. Among authors: van norden y, van den bent mj. J Neurol. 2009 Feb;256(2):279-82. doi: 10.1007/s00415-009-0051-y. Epub 2009 Feb 27. J Neurol. 2009. PMID: 19252764 No abstract available.
Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis.
Schuurmans M, Bromberg JE, Doorduijn J, Poortmans P, Taphoorn MJ, Seute T, Enting R, van Imhoff G, van Norden Y, van den Bent MJ. Schuurmans M, et al. Among authors: van imhoff g, van norden y, van den bent mj. Br J Haematol. 2010 Oct;151(2):179-84. doi: 10.1111/j.1365-2141.2010.08328.x. Epub 2010 Aug 25. Br J Haematol. 2010. PMID: 20738305 Free article.
Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients.
Franckena M, Lutgens LC, Koper PC, Kleynen CE, van der Steen-Banasik EM, Jobsen JJ, Leer JW, Creutzberg CL, Dielwart MF, van Norden Y, Canters RA, van Rhoon GC, van der Zee J. Franckena M, et al. Among authors: van norden y, van der zee j, van rhoon gc, van der steen banasik em. Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):242-50. doi: 10.1016/j.ijrobp.2008.03.072. Epub 2008 Nov 5. Int J Radiat Oncol Biol Phys. 2009. PMID: 18990505 Clinical Trial.
The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.
Dinmohamed AG, van Norden Y, Visser O, Posthuma EF, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M. Dinmohamed AG, et al. Among authors: van norden y, van de loosdrecht aa. Leuk Res. 2015 Feb;39(2):177-82. doi: 10.1016/j.leukres.2014.11.025. Epub 2014 Dec 4. Leuk Res. 2015. PMID: 25533930
Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.
Dinmohamed AG, van Norden Y, Visser O, Posthuma EF, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M. Dinmohamed AG, et al. Among authors: van norden y, van de loosdrecht aa. Leukemia. 2015 Dec;29(12):2449-51. doi: 10.1038/leu.2015.220. Epub 2015 Sep 15. Leukemia. 2015. PMID: 26369829 No abstract available.
Effectiveness of azacitidine in higher-risk myelodysplastic syndromes.
Dinmohamed AG, van Norden Y, van de Loosdrecht AA, Jongen-Lavrencic M. Dinmohamed AG, et al. Among authors: van norden y, van de loosdrecht aa. Leukemia. 2016 Aug;30(8):1795-6. doi: 10.1038/leu.2016.117. Epub 2016 May 20. Leukemia. 2016. PMID: 27198054 No abstract available.
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.
Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, Levin MD; HOVON CLL study group. Kater AP, et al. Among authors: van norden y, van oers mhj, van der straten l, van gelder m. Haematologica. 2019 Jan;104(1):147-154. doi: 10.3324/haematol.2018.193854. Epub 2018 Aug 16. Haematologica. 2019. PMID: 30115656 Free PMC article. Clinical Trial.
Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.
Dinmohamed AG, Visser O, van Norden Y, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M. Dinmohamed AG, et al. Among authors: van norden y, van de loosdrecht aa. Eur J Cancer. 2014 Mar;50(5):1004-12. doi: 10.1016/j.ejca.2013.12.002. Epub 2013 Dec 31. Eur J Cancer. 2014. PMID: 24388662
42 results